These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 32545874)

  • 41. Genome-wide CRISPR/Cas9 knockout screening uncovers a novel inflammatory pathway critical for resistance to arginine-deprivation therapy.
    Chu CY; Lee YC; Hsieh CH; Yeh CT; Chao TY; Chen PH; Lin IH; Hsieh TH; Shih JW; Cheng CH; Chang CC; Lin PS; Huang YL; Chen TM; Yen Y; Ann DK; Kung HJ
    Theranostics; 2021; 11(8):3624-3641. PubMed ID: 33664852
    [TBL] [Abstract][Full Text] [Related]  

  • 42. ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance.
    Huang HY; Wu WR; Wang YH; Wang JW; Fang FM; Tsai JW; Li SH; Hung HC; Yu SC; Lan J; Shiue YL; Hsing CH; Chen LT; Li CF
    Clin Cancer Res; 2013 Jun; 19(11):2861-72. PubMed ID: 23549872
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rational design, engineer, and characterization of a novel pegylated single isomer human arginase for arginine depriving anti-cancer treatment.
    Yu KM; Pang TP; Cutler M; Tian M; Huang L; Lau JY; Chung SF; Lo TW; Leung TY
    Life Sci; 2021 Jan; 264():118674. PubMed ID: 33129876
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discovery and Targeting of a Noncanonical Mechanism of Sarcoma Resistance to ADI-PEG20 Mediated by the Microenvironment.
    Rogers LC; Kremer JC; Brashears CB; Lin Z; Hu Z; Bastos ACS; Baker A; Fettig N; Zhou D; Shoghi KI; Dehner CA; Chrisinger JSA; Bomalaski JS; Garcia BA; Oyama T; White EP; Van Tine BA
    Clin Cancer Res; 2023 Aug; 29(16):3189-3202. PubMed ID: 37339179
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Decreased argininosuccinate synthetase expression in Thai patients with cholangiocarcinoma and the effects of ADI-PEG20 treatment in CCA cell lines.
    Roeksomtawin S; Navasumrit P; Waraprasit S; Parnlob V; Sricharunrat T; Bhudhisawasdi V; Savaraj N; Ruchirawat M
    Oncol Lett; 2018 Aug; 16(2):1529-1538. PubMed ID: 30008833
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bench-to-Bedside Studies of Arginine Deprivation in Cancer.
    Field GC; Pavlyk I; Szlosarek PW
    Molecules; 2023 Feb; 28(5):. PubMed ID: 36903394
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Arginine deprivation by arginine deiminase of Streptococcus pyogenes controls primary glioblastoma growth in vitro and in vivo.
    Fiedler T; Strauss M; Hering S; Redanz U; William D; Rosche Y; Classen CF; Kreikemeyer B; Linnebacher M; Maletzki C
    Cancer Biol Ther; 2015; 16(7):1047-55. PubMed ID: 25774632
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PEGylation increases antitumoral activity of arginine deiminase of Streptococcus pyogenes.
    Schwarz R; Zitzow E; Fiebig A; Hering S; Humboldt Y; Schoenwaelder N; Kämpfer N; Volkmar K; Hinz B; Kreikemeyer B; Maletzki C; Fiedler T
    Appl Microbiol Biotechnol; 2022 Jan; 106(1):261-271. PubMed ID: 34910240
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Amino Acids Sequence-based Analysis of Arginine Deiminase from Different Prokaryotic Organisms: An In Silico Approach.
    Abdollahi S; Morowvat MH; Savardashtaki A; Irajie C; Najafipour S; Zarei M; Ghasemi Y
    Recent Pat Biotechnol; 2020; 14(3):235-246. PubMed ID: 32208128
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pegylated arginine deiminase: a novel anticancer enzyme agent.
    Feun L; Savaraj N
    Expert Opin Investig Drugs; 2006 Jul; 15(7):815-22. PubMed ID: 16787144
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors.
    Tomlinson BK; Thomson JA; Bomalaski JS; Diaz M; Akande T; Mahaffey N; Li T; Dutia MP; Kelly K; Gong IY; Semrad T; Gandara DR; Pan CX; Lara PN
    Clin Cancer Res; 2015 Jun; 21(11):2480-6. PubMed ID: 25739672
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies.
    Yao S; Janku F; Subbiah V; Stewart J; Patel SP; Kaseb A; Westin SN; Naing A; Tsimberidou AM; Hong D; Piha-Paul SA; Shi N; Johnston A; Bomalaski J; Fu S
    Br J Cancer; 2021 Apr; 124(9):1533-1539. PubMed ID: 33674736
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties.
    Holtsberg FW; Ensor CM; Steiner MR; Bomalaski JS; Clark MA
    J Control Release; 2002 Apr; 80(1-3):259-71. PubMed ID: 11943403
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Phase 1 study of ADI-PEG20 (pegargiminase) combined with cisplatin and pemetrexed in ASS1-negative metastatic uveal melanoma.
    Chan PY; Phillips MM; Ellis S; Johnston A; Feng X; Arora A; Hay G; Cohen VML; Sagoo MS; Bomalaski JS; Sheaff MT; Szlosarek PW
    Pigment Cell Melanoma Res; 2022 Jul; 35(4):461-470. PubMed ID: 35466524
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies.
    Izzo F; Marra P; Beneduce G; Castello G; Vallone P; De Rosa V; Cremona F; Ensor CM; Holtsberg FW; Bomalaski JS; Clark MA; Ng C; Curley SA
    J Clin Oncol; 2004 May; 22(10):1815-22. PubMed ID: 15143074
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Arginine starvation impairs mitochondrial respiratory function in ASS1-deficient breast cancer cells.
    Qiu F; Chen YR; Liu X; Chu CY; Shen LJ; Xu J; Gaur S; Forman HJ; Zhang H; Zheng S; Yen Y; Huang J; Kung HJ; Ann DK
    Sci Signal; 2014 Apr; 7(319):ra31. PubMed ID: 24692592
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis.
    Delage B; Luong P; Maharaj L; O'Riain C; Syed N; Crook T; Hatzimichael E; Papoudou-Bai A; Mitchell TJ; Whittaker SJ; Cerio R; Gribben J; Lemoine N; Bomalaski J; Li CF; Joel S; Fitzgibbon J; Chen LT; Szlosarek PW
    Cell Death Dis; 2012 Jul; 3(7):e342. PubMed ID: 22764101
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Arginine deiminase expressed in vivo, driven by human telomerase reverse transcriptase promoter, displays high hepatoma targeting and oncolytic efficiency.
    Jiang H; Guo S; Xiao D; Bian X; Wang J; Wang Y; Zhou H; Cai J; Zheng Z
    Oncotarget; 2017 Jun; 8(23):37694-37704. PubMed ID: 28455966
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cloning, expression, and characterization of a thermostable l-arginase from Geobacillus thermodenitrificans NG80-2 for l-ornithine production.
    Huang K; Mu W; Zhang T; Jiang B; Miao M
    Biotechnol Appl Biochem; 2016 May; 63(3):391-7. PubMed ID: 25908562
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhibition of ornithine decarboxylase 1 facilitates pegylated arginase treatment in lung adenocarcinoma xenograft models.
    Lam SK; U KP; Li YY; Xu S; Cheng PN; Ho JC
    Oncol Rep; 2018 Oct; 40(4):1994-2004. PubMed ID: 30066894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.